Eligard

NEW YORK (Reuters Health) - Older men who opt for hormone-blocking therapy to treat prostate cancer might be slightly raising their risk of developing cataracts, hints new research.

NEW YORK (Reuters Health) - Men who opt for hormone-blocking therapy to treat prostate cancer may be increasing their risk of developing colon cancer, hints a study published this week in the Journal of the National Cancer Institute.

NEW YORK (Reuters Health) - Men who opt for hormone-blocking therapy to treat prostate cancer may be increasing their risk of developing colon cancer, hints a study published this week in the Journal of the National Cancer Institute.

WASHINGTON (Reuters) - Hormone treatments for prostate cancer need new warnings about a small increased risk of diabetes and heart problems including sudden death, U.S. health officials said on Wednesday.

WASHINGTON (Reuters) - The U.S. Food and Drug Administration is examining if certain hormone treatments for men with prostate cancer pose a greater risk of diabetes or heart problems than other therapies.

WASHINGTON (Reuters) - Roche Holding AG, Sanofi-Aventis SA and Adolor Corp made misleading claims about cancer, HIV and bowel drugs, U.S. regulators said in letters released on Friday.

Some shareholders made more than a few pennies on a copper acquisition Friday, while a biotech stock surged on a FDA agreement. . Stockhouse Canadian Small and Micro-cap Stock Report for Friday, October 2, 2009

QLT says it sold US business, which treats prostate cancer symptoms, to Tolmar Holdings. Biotechnology company QLT Inc. said Thursday it sold its U.S. business to Tolmar Holding Inc. in a deal worth as much as $230 million.